Catherine E. Woteki has recently filed a report detailing her transaction involving shares of Neogen Corp, a company known for its work in the life sciences sector. This filing, dated October 30, 2026, reveals the acquisition of 1,776 shares at a price of $12.21 each on October 29, 2026. Such transactions are significant as they reflect the ongoing investment strategies of key individuals within the company.

Woteki, who serves as a director at Neogen Corp, has been active in managing her stock holdings in the company. The filing indicates that following this transaction, she owns a total of 29,507 shares. This activity may suggest confidence in Neogen's future prospects, particularly within the competitive landscape of in vitro and in vivo diagnostic substances.

Background

Neogen Corp, identified by CIK 0000711377, operates in the life sciences sector, specifically focusing on in vitro and in vivo diagnostic substances, classified under SIC 2835. The company is based in Lansing, Michigan, and has been publicly traded, with its stock symbol being NEOG. Recent filings indicate that Woteki has been consistently managing her equity in the company, with multiple reports filed throughout the previous years.

What the Filing Says

The SEC filing reveals that Woteki acquired 1,776 shares of Neogen Corp's common stock, which were settled for an equal number of shares of restricted stock units (RSUs) that vested on the same date. The filing notes, “Each RSU is the economic equivalent of one share of common stock.” This transaction reflects Woteki's direct ownership of the shares.

Impact

This transaction may influence Neogen Corp's market perception, particularly as it highlights the commitment of its directors to the company. Stakeholders and investors may view Woteki's actions as a positive signal regarding the company's stability and growth potential. Furthermore, as Neogen operates within a competitive landscape, such transactions can impact investor sentiment across the sector.

What's Next

The filing does not say what happens next regarding Woteki's investment strategy or any potential implications for Neogen Corp.